Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/ calmodulin signaling

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Kaminskyy, V O ^a   Surova, O V ^a   Piskunova, T ^a   Zborovskaya, I B ^b,c   Tchevkina, E M ^b,c   Andera, L ^d   Zhivotovsky, B ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c LOMONOSOV MOSCOW STATE UNIVERSITY   (Russian Federation)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

C FLIPS; Calcium; Calmodulin; DR4; Lung adenocarcinoma; TRAIL

Indexed keywords

CALMODULIN; CASPASE 8; CYCLOHEXIMIDE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FLICE INHIBITORY PROTEIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROCASPASE 8; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; CALCIUM; CFLAR PROTEIN, HUMAN; PROTEIN SYNTHESIS INHIBITOR; RECOMBINANT PROTEIN;

CALCIUM CELL LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIVITY; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; APOPTOSIS; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CALCIUM; CALMODULIN; CARCINOMA, NON-SMALL-CELL LUNG; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; CYCLOHEXIMIDE; HUMANS; LUNG NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

MLCS; MLOWN;

EID: 84875885249     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.51     Document Type: Review

References (34)

1. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
2. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005; 280: 14507-14513.
3. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95- induced apoptosis. J Biol Chem 1999; 274: 1541-1548.
4. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 2009; 16: 1352-1361.
5. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28: 1527-1533.
6. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4442-4451.
7. Paz-Ares L, Torres JMS, Diaz-Padilla I, Links M, Reguart N, Boyer M et al. Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: 19048 (Meeting abstract).
8. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434-7439.
9. Ehrenschwender M, Siegmund D, Wicovsky A, Kracht M, Dittrich-Breiholz O, Spindler V et al. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8- mediated ROCK activation. Cell Death Differ 2010; 17: 1435-1447.
10. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290: G129-G136.
11. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010; 52: 550-561.
12. Chi HC, Chen SL, Liao CJ, Liao CH, Tsai MM, Lin YH et al. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death Differ 2012; 19: 1802-1814.
13. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32: 1450-1458.
14. Pintzas A, Zhivotovsky B, Linardopoulos S, Martinou JC, Lacal JC, Robine S et al. Sensitization of (colon) cancer cells to death receptor related therapies: A report from the FP6-ONCODEATH research consortium. Cancer Biol Ther 2012; 13: 458-466.
15. Liu GX, Sheng HF, Wu S. A study on the levels of calmodulin and DNA in human lung cancer cells. Br J Cancer 1996; 73: 899-901.
16. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
17. Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 2010; 9: 87.
18. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL- 28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008; 27: 490-498.
19. Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B et al. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 2009; 15: 5457-5465.
20. Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005; 3: 335-343.
21. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212.
22. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782.
23. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714.
24. Fricker N, Beaudouin J, Richter P, Eils R, Krammer PH, Lavrik IN. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J Cell Biol 2010; 190: 377-389.
25. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol 2004; 172: 2194-2200.
26. Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J Immunol 2000; 165: 6293-6300.
27. Ueffing N, Schuster M, Keil E, Schulze-Osthoff K, Schmitz I. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008; 112: 690-698.
28. Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002; 510: 37-40.
29. Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ 2006; 13: 260-272.
30. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005; 280: 27345-27355.
31. Yang BF, Xiao C, Roa WH, Krammer PH, Hao C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem 2003; 278: 7043-7050.
32. Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A et al. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 2009; 16: 1215-1226.
33. Pawar PS, Micoli KJ, Ding H, Cook WJ, Kappes JC, Chen Y et al. Calmodulin binding to cellular FLICE-like inhibitory protein modulates Fas-induced signalling. Biochem J 2008; 412: 459-468.
34. Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 2012; 19: 36-41.